Bayer Schering Pharma and Chinese Anti-Cancer Association recently kicked off the "dandelion program", which aims to promote the widespread adoption of the consensus on bone metastasis in malignant tumor and bone-related diseases diagnosis. The program will bring international updates of standardized treatment concepts to 2,000 clinical physicians to enrich their clinical experience in cancer treatment such as palliative treatment skills for active cancer symptoms and pain relief. At the same time, it will strengthen the capability of tumor patients and their relatives to identify false medical information and to understand relevant anti-cancer knowledge. (Click here for more - Chinese language)
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.
